ATE360004T1 - Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften - Google Patents

Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Info

Publication number: ATE360004T1
Authority: AT; Austria
Prior art keywords: sub; sup; alkyl; heteroaryl; halogen
Prior art date: 2001-11-28

Application number

AT02779772T

Other languages

English (en)

Inventor

Michela Bettati

Mark Stuart Chambers

Alexander Charles Humphries

Philip Irbm Jones

Richard Thomas Lewis

Robert James Maxey

Helen Jane Szekeres

Martin Richard Teall

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-28

Filing date

2002-11-27

Publication date

2007-05-15

2002-11-27 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE360004T1 publication Critical patent/ATE360004T1/de

Links

239000003446 ligand Substances 0.000 title abstract 2
230000001149 cognitive effect Effects 0.000 title 1
150000005232 imidazopyridines Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 6
229910052736 halogen Inorganic materials 0.000 abstract 5
150000002367 halogens Chemical class 0.000 abstract 5
125000001072 heteroaryl group Chemical group 0.000 abstract 5
125000000623 heterocyclic group Chemical group 0.000 abstract 3
239000004215 Carbon black (E152) Substances 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229930195733 hydrocarbon Natural products 0.000 abstract 2
150000002430 hydrocarbons Chemical class 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
102000004300 GABA-A Receptors Human genes 0.000 abstract 1
108090000839 GABA-A Receptors Proteins 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT02779772T 2001-11-28 2002-11-27 Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften ATE360004T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0128499.1A GB0128499D0 (en)	2001-11-28	2001-11-28	Therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE360004T1 true ATE360004T1 (de)	2007-05-15

Family

ID=9926615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02779772T ATE360004T1 (de)	2001-11-28	2002-11-27	Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Country Status (10)

Country	Link
US (1)	US20060040940A1 (de)
EP (1)	EP1451161B1 (de)
JP (1)	JP2005518369A (de)
AT (1)	ATE360004T1 (de)
AU (1)	AU2002343110B2 (de)
CA (1)	CA2468893A1 (de)
DE (1)	DE60219672T2 (de)
ES (1)	ES2284941T3 (de)
GB (1)	GB0128499D0 (de)
WO (1)	WO2003048132A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE350382T1 (de) *	2003-07-25	2007-01-15	Neurogen Corp	Imidazopyrimidine und triazolopyrimidine: benzodiazepinrezeptorliganden
CN100457756C (zh) *	2003-07-25	2009-02-04	神经能质公司	咪唑-嘧啶类及三唑-嘧啶类:苯并二氮平受体配体
EP1880998A1 (de) *	2003-07-25	2008-01-23	Neurogen Corporation	Imidazo-Pyrimide und Triazolo-Pyrimide: Benzodiazepin-Rezeptorliganden
US7329662B2 (en) *	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine
GB0412769D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
PT1863818E (pt)	2005-03-23	2010-04-09	Hoffmann La Roche	Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
ATE463495T1 (de)	2005-09-27	2010-04-15	Hoffmann La Roche	Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
US7563797B2 (en)	2006-08-28	2009-07-21	Forest Laboratories Holding Limited	Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
CN101679408B (zh)	2006-12-22	2016-04-27	Astex治疗学有限公司	作为fgfr抑制剂的双环杂环化合物
JP5442449B2 (ja)	2006-12-22	2014-03-12	アステックス、セラピューティックス、リミテッド	新規化合物
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
EA201000615A1 (ru)	2007-10-17	2010-12-30	Новартис Аг	Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
WO2009086123A1 (en) *	2007-12-21	2009-07-09	Wyeth	Imidazo [1,2-a] pyridine compounds
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
US8222246B2 (en) *	2009-04-02	2012-07-17	Hoffmann-La Roche Inc.	Substituted isoxazoles
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
US8785435B2 (en)	2011-10-20	2014-07-22	Hoffmann-La Roche Inc.	Solid forms
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain
EP2968299B1 (de)	2013-03-15	2021-01-20	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
BR112015021982B1 (pt)	2013-03-15	2022-12-13	Global Blood Therapeutics, Inc	Compostos e seus usos para a modulação de hemoglobina
GB201321736D0 (en)	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321732D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
AP2016009261A0 (en)	2014-02-07	2016-06-30	Global Blood Therapeutics Inc	Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
PL3383392T3 (pl)	2015-12-04	2025-11-17	Global Blood Therapeutics, Inc.	Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
KR102740831B1 (ko)	2017-11-14	2024-12-11	칠드런'즈 메디컬 센터 코포레이션	신규 이미다조피리미딘 화합물 및 그의 용도
KR102775718B1 (ko)	2017-11-14	2025-03-06	칠드런'즈 메디컬 센터 코포레이션	인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
AU2021320860A1 (en)	2020-08-05	2023-02-23	The General Hospital Corporation	Salt inducible kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9503601D0 (en) *	1995-02-23	1995-04-12	Merck Sharp & Dohme	Method of treatment and method of manufacture of medicament
EP0915875B1 (de) *	1996-07-25	2003-04-09	MERCK SHARP & DOHME LTD.	Substituierte Triazolo-Pyridazin-Derivate als Liganden von GABA-Rezeptoren
EP0915877A1 (de) *	1996-07-25	1999-05-19	MERCK SHARP & DOHME LTD.	Substituierte triazolo-pyridazinderivate als inverse agonisten des gaba-a alpha-5 rezeptor subtyps
WO1998050385A1 (en) *	1997-05-08	1998-11-12	Merck Sharp & Dohme Limited	SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
US6448249B1 (en) *	1998-02-25	2002-09-10	Merck Sharp & Dohme Ltd.	Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands
GB9824897D0 (en) *	1998-11-12	1999-01-06	Merck Sharp & Dohme	Therapeutic compounds
GB9927687D0 (en) *	1999-11-23	2000-01-19	Merck Sharp & Dohme	Therapeutic agents
US6355638B1 (en) *	1999-11-25	2002-03-12	Merck Sharp & Dohme Ltd.	Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
WO2001090108A1 (en) *	2000-05-24	2001-11-29	Merck Sharp & Dohme Limited	3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
GB0017518D0 (en) *	2000-07-17	2000-08-30	Merck Sharp & Dohme	Therapeutic agents
GB0017543D0 (en) *	2000-07-17	2000-09-06	Merck Sharp & Dohme	Therapeutic agents
GB0117277D0 (en) *	2001-07-16	2001-09-05	Merck Sharp & Dohme	Therapeutic agents
AU1253002A (en) *	2000-11-10	2002-05-21	Merck Sharp & Dohme	Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) *	2001-03-21	2006-02-11	Merck Sharp & Dohme	Imidazo-pyrimidine derivatives as ligands for GABA receptors
GB0125086D0 (en) *	2001-10-18	2001-12-12	Merck Sharp & Dohme	Novel compounds
GB0225501D0 (en) *	2002-11-01	2002-12-11	Merck Sharp & Dohme	Therapeutic agents
WO2004041826A1 (en) *	2002-11-06	2004-05-21	Merck Sharp & Dohme Limited	Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
US6967255B2 (en) *	2004-02-06	2005-11-22	Industrial Technology Research Institute	Phenanthrene compounds

2001
- 2001-11-28 GB GBGB0128499.1A patent/GB0128499D0/en not_active Ceased
2002
- 2002-11-27 EP EP02779772A patent/EP1451161B1/de not_active Expired - Lifetime
- 2002-11-27 JP JP2003549324A patent/JP2005518369A/ja active Pending
- 2002-11-27 AU AU2002343110A patent/AU2002343110B2/en not_active Ceased
- 2002-11-27 CA CA002468893A patent/CA2468893A1/en not_active Abandoned
- 2002-11-27 AT AT02779772T patent/ATE360004T1/de not_active IP Right Cessation
- 2002-11-27 US US10/497,002 patent/US20060040940A1/en not_active Abandoned
- 2002-11-27 ES ES02779772T patent/ES2284941T3/es not_active Expired - Lifetime
- 2002-11-27 WO PCT/GB2002/005337 patent/WO2003048132A1/en not_active Ceased
- 2002-11-27 DE DE60219672T patent/DE60219672T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20060040940A1 (en)	2006-02-23
CA2468893A1 (en)	2003-06-12
EP1451161B1 (de)	2007-04-18
EP1451161A1 (de)	2004-09-01
DE60219672D1 (de)	2007-05-31
AU2002343110A1 (en)	2003-06-17
DE60219672T2 (de)	2007-12-27
JP2005518369A (ja)	2005-06-23
GB0128499D0 (en)	2002-01-23
AU2002343110B2 (en)	2008-10-30
ES2284941T3 (es)	2007-11-16
WO2003048132A1 (en)	2003-06-12

Legal Events

Date	Code	Title	Description
2007-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60219672D1 (de)	2007-05-31	Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
RU2309951C2 (ru)	2007-11-10	Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
AR037682A1 (es)	2004-12-01	Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
EA200201179A1 (ru)	2003-04-24	Производные 2-аминокарбонил-9h-пурина
DK1261602T3 (da)	2004-08-30	Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
BR0314392A (pt)	2005-07-12	Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
ATE139233T1 (de)	1996-06-15	Annelierte thiophen-derivate, ihre herstellung und verwendung
HK1041257A1 (zh)	2002-07-05	作為nk-3受體拮抗劑的喹啉-4-酰胺衍生物
BG107171A (bg)	2003-07-31	Производни на пурин
AR035935A1 (es)	2004-07-28	El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende
EA200700099A1 (ru)	2007-08-31	Производные пиридина
RU2008112691A (ru)	2009-10-10	Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
EA200000700A3 (ru)	2001-04-23	НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ
DE602004012758D1 (de)	2008-05-08	Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE530187T1 (de)	2011-11-15	Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern
ATE530182T1 (de)	2011-11-15	Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
TR200000727T2 (tr)	2000-09-21	5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi.
WO2005040345A3 (en)	2005-08-18	4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EA200401455A1 (ru)	2005-06-30	Производные бензоксазина в качестве модуляторов 5-htи их применение
DE60014394D1 (de)	2004-11-04	Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
MX2012008147A (es)	2012-08-03	Derivados de pirrazolopiridina.
AR059490A1 (es)	2008-04-09	Cmpuestos antivirales heterociclicos
TW200510320A (en)	2005-03-16	Aminoquinoline derivatives and their use as adenosine A3 ligands
AR037611A1 (es)	2004-11-17	Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
ATE287397T1 (de)	2005-02-15	Chinoline derivate und ihre anwendung als antitumor agentien